5 Key Takeaways
-
1
Avisi Technologies is developing vision-saving technologies based on metamaterial nanotechnology from the University of Pennsylvania.
-
2
The VisiPlate Aqueous Shunt is an ultrathin device designed to control intraocular pressure by wicking aqueous into a drainage space.
-
3
Avisi is currently enrolling patients in the SAPPHIRE study to evaluate the VisiPlate Aqueous Shunt in refractory primary open-angle glaucoma.
-
4
The VisiPlate technology has demonstrated effective intraocular pressure control and safety in the VITA study, with results lasting up to two years.
-
5
Avisi Technologies aims to create a new paradigm in glaucoma care with innovative, biocompatible devices that address the disease's unique challenges.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.